Patient Name : MRS. VALAVALA DURGA RANI		Referral : SEL	F		
Age / Gender : 39 years / Female		Collection Tim	Collection Time : Dec 10, 2022, 09:05 a.m.		
Patient ID: 13586		Reporting Tim	e : Dec 10, 2022, 02:55 p.m.		
Source : MEDI WHEEL		Sample ID :			
Test Description	Value(s)	Reference Range	Unit		
Esr, Erythrocyte Sedimentation Rate					
Esr, Erythrocyte Sedimentation Rate (Westergren)	23	0-30	mm/hr		
Interpretation:					
 It indicates presence and intensity of an inflam more significant than the abnormal results of a 		It does not diagnose a specif	ic disease. Changes in the ESR are		
• It is a prognostic test and used to monitor the or endocarditis, acute rheumatic fever, rheumator	•				
• It is also increased in pregnancy, multiple mye	loma, menstruat	ion, and hypothyroidism.			
Blood Group & Rh Type					
Blood Grouping & Rh Typing Method : Forward and Reverse By Tube Method	"O" + (POSI	TIVE)			
Methodology	uha Agglutinatia	n mathad			
This is done by forward and reverse grouping by t Interpretation	ube Aggiutinatio	in method.			
Newborn baby does not produce ABO ar Newborn baby is done by ABO antigen g grouping) is not required.Confirmation of expression and the isoagglutinins are full	rouping (forw the New-bori	vard grouping) only, antib n's blood group is indicat	ody grouping (reverse		

Fasting - Glucose

Glucose Fasting* Method : Plasma, Hexokinase

85

Normal: 70-110 Impaired Fasting Glucose (IFG): 110-125 Diabetes Mellitus: >= 126 (On more than one occasion) (American Diabetes Association guidelines 2017)

Auptri

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



mg/dL

Age / Gender : 39 years / Female

Patient ID: 13586

Referral : SELF

Collection Time : Dec 10, 2022, 09:05 a.m.

Reporting Time : Dec 10, 2022, 02:55 p.m.

Sample ID : Source : MEDI WHEEL 668420096 **Test Description** Value(s) **Reference Range** Unit

Lipid Profile			
Cholesterol-Total Method : Serum, Cholesterol oxidase esterase, peroxi	156 dase	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	189	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
Cholesterol-HDL Direct Method : Serum, Direct measure-PEG	44	Normal: > 40 Major Heart Risk: < 40	mg/dL
LDL Cholesterol Method : Serum	74.2	Optimal: < 100 mg/dL Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	
Non - HDL Cholesterol, Serum Method : calculated	112	Desirable: < 130 mg/dL mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	
VLDL Cholesterol Method : calculated	37.8	6 - 38	mg/dL
CHOL/HDL RATIO Method : calculated	3.55	3.5 - 5.0	ratio

Otrepter

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender : 39 years / Female

Patient ID: 13586

Source : MEDI WHEEL

Referral : SELF

Collection Time : Dec 10, 2022, 09:05 a.m.

Reporting Time : Dec 10, 2022, 02:55 p.m.

Sample ID :

			00420030
Test Description	Value(s)	Reference Range	Unit
LDL/HDL RATIO	1.69	Desirable / low risk - 0.5 -3.0	ratio
Method : calculated		Low/ Moderate risk - 3.0- 6.0	
		Elevated / High risk - > 6.0	
HDL/LDL RATIO	0.59	Desirable / low risk - 0.5 -3.0	ratio
Method : calculated		Low/ Moderate risk - 3.0- 6.0	
		Elevated / High risk - > 6.0	
Note: 8-10 hours fasting sample is required.			
Liver Function Test			
Bilirubin - Total	0.6	Adults and Children: < 1.2	mg/dL
Method : Serum, Diazotization			
Bilirubin - Direct	0.2	Adults and Children: < 0.5	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.4	0.1 - 1.0	mg/dL
Method : Serum, Calculated			
SGOT	26	< 50	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	19	< 50	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase-ALPI	68	30-120	U/L
Method : Serum, PNPP, AMP Buffer, IFCC 37 degree			
GGT-Gamma Glutamyl Transpeptidae	22	< 55	U/L
Method : Serum, G-glutamyl-carboxy-nitoanilide			
Total Protein	7.5	6.6 - 8.3	g/dL
Method : Serum, Biuret, reagent blank end point			
Albumin	4.3	Adults: 3.5 - 5.2	g/dL
Method : Serum, Bromcresol purple			
Globulin	3.2	1.8 - 3.6	g/dL
Method : Calculated			

Otespeti

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender : 39 years / Female

Patient ID: 13586

Source : MEDI WHEEL

Referral : SELF

Sample ID :

Collection Time : Dec 10, 2022, 09:05 a.m.

Reporting Time : Dec 10, 2022, 02:55 p.m.

668420096

Test Description	Value(s)	Reference Range	Unit
A/G Ratio	1.34	1.2 - 2.2	ratio
Method : Calculated	1.34	1.2 - 2.2	Talio
KIDNEY FUNCTION TEST			
Urea *	16	15- 50	mg/dL
Method : Serum			g,
Blood Urea Nitrogen-BUN*	7.4	7 - 24	mg/dL
Method : Serum, Urease			
Uric Acid*	5.2	2.6 - 6.0	mg/dL
Method : Serum, Uricase/POD			
Creatinine*	0.67	0.6 - 1.1	mg/dL
Method : Serum, Jaffe IDMS			
Urine Routine			
Colour*	Yellow		
Volume*	15	-	ml
Transparency (Appearance)*	Clear	Clear	
Deposit*	Absent	Absent	
Reaction (pH)*	5.0	4.5 - 8	
Specific Gravity*	1.025	1.010 - 1.030	
Chemical Examination (Automated Dig	ostick Method) Urine		
Urine Glucose*	Negative	Negative	
Urine Protein*	Negative	Negative	
Blood*	Negative	Negative	
Urine Ketone*	Negative	Negative	
Blood*	Negative	Negative	
Bilirubin*	Negative	Negative	
	-	5	

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Patient Name : MRS. VALAVALA DURGA RANI Age / Gender : 39 years / Female Patient ID : 13586

Referral : SELF

Sample ID :

Collection Time : Dec 10, 2022, 09:05 a.m.

Reporting Time : Dec 10, 2022, 02:55 p.m.

Source : MEDI WHEEL

Test Description	Value(s)	Reference Range	Unit
Leucocytes*	Negative	Negative	
Urobilinogen*	Normal	With in normal limits	
Microscopic Examination Urine			
Pus Cells (WBCs)*	2-3	0 - 5	/hpf
Epithelial Cells*	1-2	0 - 4	/hpf
Red blood Cells*	Absent	Absent	/hpf
Crystals*	Absent	Absent	
Cast*	Absent	Absent	
Trichomonas Vaginalis*	Absent	Absent	
Yeast Cells*	Absent	Absent	
Amorphous deposits*	Absent	Absent	
Bacteria*	Absent	sent Absent	

Thyroid Function Test (TFT)

THYROID STIMULATING HORMONE (TSH) 8.41 Method : CLIA 0.46 - 8.10 : 1 Yrs - 5 Yrs 0.36 - 5.80 : 6 Yrs - 18 Yrs 0.35 - 5.50 : 18 Yrs - 55 Yrs 0.50 - 8.90 : >55 Yrs Pregnancy Ranges:::: Ist Tri :0.1 - 2.5 IInd Tri :0.2 - 3.0 IIIrd Tri:0.3 - 3.0 uIU/mL

Otrepti

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender : 39 years / Female

Patient ID: 13586

Source : MEDI WHEEL

Referral : SELF

Collection Time : Dec 10, 2022, 09:05 a.m.

Reporting Time : Dec 10, 2022, 02:55 p.m.



			668420096
Test Description	Value(s)	Reference Range	Unit
TOTAL TRI-IODOTHYRONINE (T3)	138	126 – 258 : 1 Yr – 5 Yr	ng/dl
Method : CLIA		96 – 227 : 6 Yr – 15 Yr	
		91 – 164 : 16 Yr – 18 Yr	
		60 – 181 : > 18 Years	
		Pregnancy :	
		1st Trimester : 81 - 190	
		2nd & 3rd Trimester:100 - 260	
TOTAL THYROXINE (T4)	5.2		μg/dL
Method : CLIA		4.6 - 10.9	
		Pregnancy:	
		4.6 – 16.5 : 1st Trimester	
		4.6 – 18.5 : 2nd & 3rd Tri	

Comments:

IF NOT ON DRUGS SUGGESTED FT3 & FT4 ESTIMATION

Please correlate with clinical conditions.

Note : Serum T3, T4 and TSH form the three components of thyroid screening panel, useful in diagnosing various disorders of the thyroid gland. Primary Hypothyroidism is accompanied by depressed serum T3 and T4 values and elevated serum TSH levels. Although elevated TSH levels are nearly always indicative of Primary Hypothyroidism, rarely they can from TSH secreting pituitary tumors (Secondary hyperthyroidism)To confirm diagnosis - evaluate FT3 and FT4.

Post Prandial Urine Sugar			
Post Prandial Urine Sugar	NEGATIVE		
Post Prandial Blood Sugar			
Blood Glucose-Post Prandial*	111	70-140	mg/dL
Method : Plasma - P, Hexokinase			

END OF REPORT

aprip

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by

